If at first you don’t succeed, sue and sue again. That seems to be the J&J credo these days.
Last week, I couldn’t help but notice that Johnson & Johnson sued Abbott Labs for patent infringement in an attempt to keep Abbott’s Xience stent off the market. Again. J&J is investing heavily in litigations these days. One has to wonder if “Litigation Before Innovation” has been added as a pillar to the new J&J credo.
Of course, we also know that the FDA Advisory Committee panel has now backed approval of Xience. (See Abbott press release ) Although, just because an FDA Advisory Committee panel backs a drug on the basis of safety and efficacy, doesn’t mean the FDA will actually approve.